Ann & Robert H Lurie Children's Hospital of Chicago
luriechildrens.orgTotal trials
181
Active
51
Phase 3
7
Total enrollment
41,719
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Recombinant Zoster Vaccine | — | — | — | — | — | 1 | |
| Combination therapy | — | — | — | — | — | 1 | |
| Trametinib and Nivolumab | — | — | — | — | — | 1 | |
| Dabrafenib, trametinib, nivolumab | — | — | — | — | — | 1 | |
| Tylenol | — | — | — | — | — | 1 | |
| Atropine | — | — | — | — | — | 1 | |
| Anakinra | — | — | — | — | — | 1 | |
| Cytalux | — | — | — | — | — | 1 | |
| rHSC-DIPGVax | — | — | — | — | — | 1 | |
| Balstilimab | — | — | — | — | — | 1 | |
| Zalifrelimab | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG | — | — | — | — | — | 1 | |
| Saccharomyces Boulardii 250 MG [Florastor] | — | — | — | — | — | 1 | |
| trimethoprim-sulfamethoxazole | — | — | — | — | — | 1 | |
| Dose | — | — | — | — | — | 1 |
Next readouts
- 2018-12
- 2024-12-31
- 2025-08-31
- 2026-01-20
- 2026-03-13
- 2026-06-01
- 2026-09
- 2027-03-31
- 2027-05
- 2028-12
Top conditions
- Sickle Cell Disease6
- Eosinophilic Esophagitis6
- Leukemia6
- Cancer5
- Sickle B+ Thalassemia4
- Sickle Beta Zero Thalassemia4
- Sickle Cell Hemoglobin C4
- HIV4
Frequently asked questions about Ann & Robert H Lurie Children's Hospital of Chicago
- How many clinical trials does Ann & Robert H Lurie Children's Hospital of Chicago have on ClinicalTrials.gov?
- Ann & Robert H Lurie Children's Hospital of Chicago is listed as the lead sponsor on 181 clinical trials in ClinicalTrials.gov, 51 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ann & Robert H Lurie Children's Hospital of Chicago's trials are in Phase 3?
- 7 of Ann & Robert H Lurie Children's Hospital of Chicago's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Ann & Robert H Lurie Children's Hospital of Chicago focus on?
- Ann & Robert H Lurie Children's Hospital of Chicago's most-studied conditions on ClinicalTrials.gov are Sickle Cell Disease, Eosinophilic Esophagitis, Leukemia, Cancer, Sickle B+ Thalassemia.
- When are Ann & Robert H Lurie Children's Hospital of Chicago's next clinical trial readouts?
- Ann & Robert H Lurie Children's Hospital of Chicago has 10 upcoming primary-completion readouts tracked here; the soonest is “Prophylactic Antibiotics or Placebo After Hypospadias Repair”, expected around 2018-12.